BeStock  

Amphastar Pharmaceuticals AMPH

$28.25 +$0.14 (+0.50%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $28.26 +0.04%
Open$28.14
Prev close$28.11
Day range$27.79 – $28.70
Volume498.5K
Market cap$1.20B
P/E (TTM)13.0
Dividend yield–

Earnings

Average move on report day±10.2%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+15.4%
Worst reaction-23.6%

Stock move on the day after each report

-14.9%2023/Q4+0.5%2024/Q1+13.3%2024/Q2-13.7%2024/Q3-9.7%2024/Q4+0.9%2025/Q1+10.1%2025/Q2-0.8%2025/Q3-23.6%2025/Q4-20.9%2026/Q1+4.9%2026/Q2+3.0%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q35 Nov 2026After Market±16.6%+3.00%Within range
2026/Q26 Aug 2026After Market–+4.90%–
2026/Q17 May 2026After Market±16.3%-20.93%Bigger than priced
2025/Q426 Feb 2026After Market±11.9%-23.63%Bigger than priced
2025/Q36 Nov 2025After Market–-0.83%–
2025/Q27 Aug 2025After Market±12.0%+10.13%Within range
2025/Q17 May 2025After Market±19.5%+0.90%Within range
2024/Q427 Feb 2025After Market±12.4%-9.72%Within range
2024/Q36 Nov 2024After Market±10.3%-13.69%Bigger than priced
2024/Q27 Aug 2024After Market±16.6%+13.29%Within range
2024/Q18 May 2024After Market±14.5%+0.52%Within range
2023/Q428 Feb 2024After Market±15.2%-14.93%Within range
2023/Q38 Nov 2023After Market±12.2%+15.39%Bigger than priced
2023/Q28 Aug 2023After Market±13.4%-4.29%Within range
2023/Q19 May 2023After Market±9.2%+13.04%Bigger than priced
2022/Q428 Feb 2023After Market±17.5%+14.75%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Other products$70.21M 33.8%
  • BAQSIMI$58.80M 28.3%
  • Primatene MIST$31.46M 15.2%
  • Lidocaine$16.64M 8.0%
  • Epinephrine$15.27M 7.4%
  • Glucagon$8.58M 4.1%
  • Ipratropium bromide$6.65M 3.2%

Latest reported quarter: Q3, ended Sep 2026

Revenue$207.61M+8.2% YoY
Operating profit$50.77M+100.5% YoY
Net profit$37.76M+117.7% YoY
Diluted EPS$0.87+135.1% YoY
Free cash flow-$61.14M-229.4% YoY
Operating cash flow$43.30M

Revenue, last 8 quarters

$186.5MDec '24$170.5MMar '25$174.4MJun '25$191.8MSep '25$183.1MDec '25$171.2MMar '26$183.9MJun '26$207.6MSep '26

Net profit, last 8 quarters

$38.0MDec '24$25.3MMar '25$31.0MJun '25$17.4MSep '25$24.4MDec '25$6.4MMar '26$30.3MJun '26$37.8MSep '26

Profitability & balance sheet

Gross margin46.8%
Operating margin18.7%
Net margin13.3%
Return on equity12.4%
Return on assets5.9%
Return on invested capital7.6%
Current ratio3.32
Liabilities / assets52.4%
Cash & investments$230.63M
Total debt$682.97M
Net cash (debt)-$452.34M
Free cash flow / sales6.0%

Discussion

No comments yet — be the first to weigh in on AMPH.

Sign in to join the discussion.

Scroll to Top